Investigation of the effect of N-acetylcysteine in rheumatoid arthritis

Study effect of N-acetylcysteine on clinical status and paraclinical outcomes in patients with rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101014004934N2

Enrollment

Registered

2020-11-25

Start date

2020-11-30

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: one tablet (600 mg) of N-acetylcysteine (Osvah, Iran) daily. Intervention 2: Control group: Patients receiving one placebo tablet daily (Barij Essence, Iran).

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient with rheumatoid arthritis 20 to 70 Years old

Exclusion criteria

Exclusion criteria: Unwillingness to cooperate Hypo or hyperthyroidism Use of any supplements (vitamins, minerals and etc) within 3 months prior to enrollment in the study Incidence of intolerable complications Current smokers

Design outcomes

Primary

Measure	Time frame
Disease activity. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: DAS28-ESR (using a questionnaire for VAS and a checklist to note physical examination results).;Hs-CRP. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Elisa kit.;ESR. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: mm/h.	—

Measure

Time frame

Disease activity. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: DAS28-ESR (using a questionnaire for VAS and a checklist to note physical examination results).;Hs-CRP. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Elisa kit.;ESR. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: mm/h.

—

Secondary

Measure	Time frame
Malondialdehyde. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Morning stiffness duration. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Minutes.	—

Measure

Time frame

Malondialdehyde. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Morning stiffness duration. Timepoint: At the beginning of the study (before the intervention) and 12 weeks after the intervention. Method of measurement: Minutes.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKamal Esalatmanesh

Kashan University of Medical Sciences

kamalesalatmanesh@kaums.ac.ir+98 31 5554 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026